Table 2 Logistic regression analysis of significant polymorphisms in different groups.

From: Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer

SNP ID

Gene

base change

Group 1a

Group 2b

OR (95% CI)

P value

Clinical outcomes

subgroup

WT

HE

HO

WT

HE

HO

rs4150558

GTF2H1

T > A

22

6

1

794

96

2

2.74(1.23–6.09)

0.013

anemia

none

rs10857

POLD3

A > C

65

46

4

342

370

107

0.55(0.39–0.76)

3.01 × 10−4

neutropenia

none

rs6592576

POLD3

G > A

65

46

4

346

366

108

0.56(0.41–0.77)

3.58 × 10−4

neutropenia

none

rs12727

RPA1

C > G

23

7

4

688

205

18

1.81(1.02–3.21)

0.044

thrombocytopenia

none

rs3219281

POLD1

G > A

21

10

3

679

222

15

1.87(1.4–3.34)

0.035

thrombocytopenia

none

rs3219341

POLD1

G > A

21

10

3

679

220

17

1.84(1.03–3.26)

0.039

thrombocytopenia

none

rs1726801

POLD1

G > A

21

10

3

676

213

17

1.86(1.05–3.30)

0.033

thrombocytopenia

none

rs3176721

XPA

C > A

92

39

4

385

86

6

1.88(1.28–2.76)

0.001

clinical benefit

AC

rs3218804

GTF2H4

G > A

102

32

1

415

62

0

2.29(1.43–3.66)

0.001

clinical benefit

AC

rs4150558

GTF2H1

T > A

0

3

0

183

18

1

23.45(2.64–208.13)

0.005

anemia

SCC

rs2290280

CCNH

C > A

1

0

2

160

37

8

28.53(1.69–481.13)

0.020

anemia

SCC

rs8067195

RPA1

A > G

1

0

2

150

46

9

6.93(1.44–33.49)

0.016

anemia

SCC

rs6416887

RPA1

A > G

1

0

2

142

52

10

6.55(1.32–32.44)

0.021

anemia

SCC

rs4150339

ERCC5

A > G

9

4

1

165

34

0

3.93(1.15–13.41)

0.029

gastrointestinal toxicity

SCC

rs3786136

RPA1

G > A

2

2

1

154

49

1

4.71(1.10–20.12)

0.037

thrombocytopenia

SCC

rs4150339

ERCC5

A > G

13

2

2

242

44

2

3.06(1.15–8.19)

0.026

gastrointestinal toxicity

TP

rs4253002

ERCC6

G > A

12

5

0

274

13

1

7.81(2.27–26.88)

0.001

gastrointestinal toxicity

TP

rs1726801

POLD1

G > A

18

11

4

192

66

2

3.03(1.59–5.77)

0.001

neutropenia

TP

rs1673041

POLD1

A > C

7

16

10

134

107

20

3.46(1.97–6.09)

1.70 × 10−5

neutropenia

TP

rs3219341

POLD1

G > A

18

11

4

193

66

2

3.03(1.59–5.75)

0.001

neutropenia

TP

rs1799793

ERCC2

G > A

2

5

0

196

26

3

7.91(2.02–30.96)

0.003

anemia

GP

rs20580

LIG1

A > C

2

15

4

110

85

19

3.21(1.53–6.74)

0.002

gastrointestinal toxicity

GP

rs4253212

ERCC6

G > A

9

3

2

175

41

1

3.31(1.26–8.72)

0.015

neutropenia

GP

rs4150558

GTF2H1

T > A

9

3

1

239

33

0

4.39(1.37–14.08)

0.013

anemia

NP

rs326222

DDB2

A > G

23

22

9

251

165

15

2.07(1.32–3.23)

0.001

neutropenia

age ≤ 58

rs12150513

RPA1

A > C

31

14

7

263

150

12

2.18(1.32–3.61)

0.002

neutropenia

age ≤ 58

rs4150339

ERCC5

A > G

34

5

3

366

61

0

2.53(1.23–5.22)

0.012

gastrointestinal toxicity

age>58

rs2296147

ERCC5

A > G

24

12

6

272

146

8

2.10(1.21–3.64)

0.008

gastrointestinal toxicity

age>58

rs4150360

ERCC5

G > A

23

13

6

266

152

9

3.07(1.70–5.55)

2.12 × 10−4

gastrointestinal toxicity

age>58

rs4771436

ERCC5

A > C

31

7

3

190

202

33

0.37(0.19–0.72)

0.003

gastrointestinal toxicity

age>58

  1. AC, Adenocarcinoma; SCC, Squamous Cell Carcinoma; TP, Paclitaxel combined with cisplatin regimen; GP, Gemcitabine combined with cisplatin regimen; NP, navelbine combined with cisplatin regimen; OR, Odd ratio; CI, Confidence interval; WT, wild type; HE, heterozygote; HO, mutant homozygote.
  2. aGroup 1 means severe toxicity in toxicity analysis, bad response in clinical benefit or response rate analysis.
  3. bGroup 2 means light toxicity in toxicity analysis, good response in clinical benefit or response rate analysis.
Back to article page